ANDA blend uniformity
Executive Summary
FDA's Advisory Committee for Pharmaceutical Science will meet Nov. 28 and 29 to discuss the agency's draft guidance "ANDAs: Blend Uniformity Analysis" along with other issues including stability testing and shelf-life, dermatopharmacokinetics and other bioequivalence issues. The meeting begins at 8:30 a.m. in CDER's advisory committee conference room at 5630 Fisher's Lane in Rockville, Md